Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Cannabinoids in the management of spasticity associated with multiple sclerosis

Authors Malfitano AM, Proto MC, Bifulco M

Published 10 October 2008 Volume 2008:4(5) Pages 847—853

DOI https://doi.org/10.2147/NDT.S3208

Review by Single anonymous peer review

Peer reviewer comments 3



Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno

Abstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In this study we highlight the main findings reported in literature about the relevance of cannabinoid drugs in the management and treatment of MS. An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. In this report we focus on the effects of cannabinoids in the relief of spasticity describing the main findings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments, although long-term studies are required to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

Keywords: cannabinoids, multiple sclerosis, spasticity

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.